Preclinical development of hybrid cell vaccines for multiple myeloma

European Journal of Haematology

Volumn 78, Issue 1, 2007, Pages 11-20

  Walewska, Renata ^a,b   Teobald, Iryna ^a   Dunnion, Debbie ^a   Abdulmajed, Hind ^a   Aldred, Micheala ^a   Sadler, Jean ^b   Chapman, Claire ^b   Browning, Michael ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cancer; Fusion; Hybrid; Immunotherapy; Multiple myeloma; Vaccine

Indexed keywords

ABATACEPT; B7 ANTIGEN; CANCER VACCINE; SYNDECAN 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOBLAST; CANCER CELL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HYBRID CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE CULTURE; TUMOR REGRESSION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CYTOGENETIC ANALYSIS; FLOW CYTOMETRY; HUMANS; HYBRID CELLS; IMMUNOLOGIC TESTS; IMMUNOPHENOTYPING; MICROSATELLITE REPEATS; MULTIPLE MYELOMA; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 33845901789     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00769.x     Document Type: Article

References (31)

1. Hoffman A (ed.) Hematology, 3rd edn. Oxford: Churchill Livingstone, 2000.
2. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000;27:598- 613.
3. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996;56:3782-7.
4. Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998;9:835-43.
5. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1195-205.
6. Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20:4549-54.
7. Curti A, Parenza M, Colombo MP. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 2003;101:568-75.
8. Michael A, Ball G, Quantan N, Wushushi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11:4469-78.
9. Edwards PAW, Smith CM, Neville AM, O'Hare MJ. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol 1982;12:641-8.
10. Dunnion DJ, Cywinski AL, Tucker VC, Murray AK, Rickinson AB, Coulie P, Browning MJ. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999;98:541-50.
11. Cywinski AL, Dunnion DJ, Teobald I, Tucker VC, Browning MJ. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro. Tissue Antigens 2006;68:115-26.
12. Benn PA, Tantravahi U. In: Rooney DE (ed). Human Cytogenetics: Constitutional Analysis. Oxford: Oxford University Press, 2001. pp 99.
13. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-6.
14. van Baren N, Brasseur F, Godelaine D. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999;94:1156- 64.
15. Pellat-Deceunynck C, Meelerin MP, Labarriere N, Jego G, Moreau-Aubry A, Harousseau JL, Jotereau F, Bataille R. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000;30:803-9.
16. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy MS. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994;263:518-20.
17. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
18. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000;165: 1705-11.
19. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003;170:1980-6.
20. Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002;99:2512-7.
21. Raje N, Hideshima T, Davies FE. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004;125:343-52.
22. Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 2005;129:687-700.
23. Phan V, Errington F, Cheong SC et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 2003;9:1215-9.
24. Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 1992;187:189-201.
25. Fabre JW, The allogeneic response and tumor immunity. Nat Med 2001;7:649-52.
26. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kirman RJ, Pardoll DM, Wu T. Antigenspecific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000;86:725-30.
27. Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:2800-7.
28. Pandha HS, Cook D, Greenhalgh R, Dalgleish A. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy. BJU Int 2005;95:1336-43.
29. Suzuki T, Fukuhara T, Tanaka M et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005;1:58-66.
30. Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nobetaner E, Willimsky G, Maget B, Pohla H, Blankenstein T. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 2000;7:2007-14.
31. Shawler DL, Bartholomew RM, Garrett MA et al. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin Exp Immunol 2002;129:99-106.